Bristol-Myers Squibb Licenses Cardiovascular Antisense Target From Isis
The latest in a string of deals for Bristol focuses on antisense targets, one of which holds promise for greater LDL cholesterol lowering, firm tells “The Pink Sheet” DAILY.
The latest in a string of deals for Bristol focuses on antisense targets, one of which holds promise for greater LDL cholesterol lowering, firm tells “The Pink Sheet” DAILY.